"Bleomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
| Descriptor ID |
D001761
|
| MeSH Number(s) |
D09.400.420.110 D12.644.233.110
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bleomycin".
Below are MeSH descriptors whose meaning is more specific than "Bleomycin".
This graph shows the total number of publications written about "Bleomycin" by people in this website by year, and whether "Bleomycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 5 | 5 |
| 1995 | 2 | 2 | 4 |
| 1996 | 4 | 2 | 6 |
| 1997 | 1 | 1 | 2 |
| 1998 | 4 | 5 | 9 |
| 1999 | 1 | 6 | 7 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 3 | 3 |
| 2002 | 1 | 10 | 11 |
| 2003 | 1 | 3 | 4 |
| 2004 | 2 | 4 | 6 |
| 2005 | 1 | 7 | 8 |
| 2006 | 1 | 8 | 9 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 6 | 8 |
| 2009 | 0 | 2 | 2 |
| 2010 | 4 | 6 | 10 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 9 | 9 |
| 2013 | 2 | 4 | 6 |
| 2014 | 2 | 10 | 12 |
| 2015 | 0 | 8 | 8 |
| 2016 | 1 | 7 | 8 |
| 2017 | 0 | 7 | 7 |
| 2018 | 0 | 9 | 9 |
| 2019 | 2 | 4 | 6 |
| 2020 | 1 | 4 | 5 |
| 2021 | 0 | 8 | 8 |
| 2022 | 1 | 10 | 11 |
| 2023 | 0 | 8 | 8 |
| 2024 | 2 | 4 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bleomycin" by people in Profiles.
-
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14. Gynecol Oncol. 2024 Nov; 190:283-290.
-
PIK-III exerts anti-fibrotic effects in activated fibroblasts by regulating p38 activation. PLoS One. 2024; 19(9):e0306624.
-
Lung cell transplantation for pulmonary fibrosis. Sci Adv. 2024 Aug 23; 10(34):eadk2524.
-
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. J Clin Oncol. 2024 Oct; 42(28):3270-3276.
-
Aging-Associated Metabolite Methylmalonic Acid Increases Susceptibility to Pulmonary Fibrosis. Am J Pathol. 2024 08; 194(8):1478-1493.
-
Cadherin-11 targeted cell-specific liposomes enabled skin fibrosis treatment by inducing apoptosis. J Control Release. 2024 Jun; 370:110-123.
-
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma. Blood Adv. 2023 12 26; 7(24):7485-7493.
-
Tuftelin1 drives experimental pulmonary fibrosis progression by facilitating stress fiber assembly. Respir Res. 2023 Dec 17; 24(1):318.
-
Single-Cell RNA Sequencing Provides New Insights into Therapeutic Roles of Thyroid Hormone in Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2023 10; 69(4):456-469.
-
Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective. JCO Oncol Pract. 2023 10; 19(10):860-870.